D70.2
Other drug-induced agranulocytosis
Clinical Classification Guidelines
Use Additional Code
- code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
Medical Intelligence & Overview
Other drug-induced agranulocytosis is a rare but serious condition characterized by a dramatic decrease in the number of granulocytes, a type of white blood cell essential for fighting infections. This condition often results from adverse reactions to certain medications, leading to a weakened immune system. Recognizing the signs and understanding the causes can be critical for prompt management and prevention of complications.
Causes & Symptoms
Clinical Causes: Use of specific medications known to affect bone marrow function Certain antibiotics, such as chloramphenicol and sulfonamides Antithyroid drugs used in the treatment of thyroid disorders Chemotherapy agents targeting cancer cells Antipsychotic medications like clozapine Some anticonvulsants and antiepileptic drugs Medications taken in conjunction with other drugs that can suppress bone marrow Pre-existing bone marrow disorders or immune system deficiencies
Key Symptoms: Fever that develops suddenly and is often high Sore throat or painful mouth ulcers Signs of infection such as chills, sweating, or skin redness Weakness and fatigue Tender or swollen lymph nodes Unusual bleeding or easy bruising General malaise or feeling unwell Rapid heart rate in severe cases
Diagnostic & Treatment
Diagnosis Path: Complete blood count (CBC) test to measure white blood cell levels, especially granulocytes Blood smear tests to examine blood cell morphology History review of recent medication use Bone marrow biopsy in some cases to assess marrow activity Infections screening to identify secondary complications Monitoring blood counts regularly if a patient is on high-risk medications
Treatment Protocols: Immediate discontinuation of the suspected drug Hospitalization may be necessary for severe cases Administration of broad-spectrum antibiotics if infection develops Use of growth factors such as granulocyte colony-stimulating factor (G-CSF) to stimulate white blood cell production Supportive care to maintain hydration and manage symptoms Monitoring blood counts closely until levels recover In some instances, caution is exercised when restarting medications or choosing alternative drugs
Clinical Advice & FAQs
Billing Guidance
Is D70.2 a billable ICD-10 code?
Yes, D70.2 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D70.2?
Clinical documentation must specify the nature of Other drug-induced agranulocytosis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference